Introduction
Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) has shown better clinical outcomes than conventional angiography-guided PCI. [1] [2] [3] [4] [5] [6] [7] [8] The optimal FFR cut-off value for revascularization is debated. With FFR < _0.80, revascularization for coronary stenosis is associated with improved clinical outcomes, whereas with FFR > _0.75, medical treatment has been shown to result in favourable long-term outcomes. 2, 3 However, there has been controversy over revascularization decision-making for coronary stenosis with FFR between 0.75 and 0.80, the so-called grey zone.
Several studies have reported the outcomes of revascularization vs. deferral for coronary stenosis with grey-zone FFR values, with conflicting results. [9] [10] [11] [12] [13] [14] [15] However, these studies were hampered by limited numbers of patients and short follow-up periods. Clinically relevant information regarding the appropriate management for this uncertain subset requires a large multicentre cohort study with longterm follow-up. In this study, we compared long-term outcomes of deferral vs. revascularization for 1334 coronary stenosis with greyzone FFR values included in a multicentre, prospective registry.
Methods
The Interventional Cardiology Research In-cooperation Society Fractional Flow Reserve (IRIS-FFR) registry is a prospective, multicentre registry designed for investigating the prognosis of coronary stenosis assessed using FFR in routine clinical practice. The inclusion and exclusion criteria of the registry have been previously described. 16 In brief, the registry consecutively enrolled all patients who underwent FFR measurement for at least one coronary lesion. The main exclusion criteria were thrombolysis in myocardial infarction (MI) flow < three, bypass graft, overt heart failure, technical unsuitability for FFR evaluation, and short life expectancy (<2 years).
For this substudy, we enrolled patients with a de novo native coronary artery stenosis with an FFR value in the grey zone (0.75-0.80). To eliminate the clustering effects of lesions within the same patient, we selected one lesion per patient, preferentially choosing those with lower FFR values, or left anterior descending arterial lesions when the FFR values were equal for two or more lesions. The study protocol was approved by the institutional review board or ethics committee of each participating centre, and all patients provided written informed consent.
Fractional flow reserve measurement and revascularization
Fractional flow reserve was measured after coronary angiography with a commercially available coronary pressure (Pd) wire, as previously described. 16 After the administration of intracoronary nitroglycerin (100 or 200 mg), the pressure wire was positioned in the distal segment of the target vessel. It was recommended that hyperaemia should be induced by intravenous adenosine infusion (140 or 200 mg/kg/min) via a central or large antecubital vein. The proximal aortic pressure (Pa) and distal Pd were measured during sustained hyperaemia, and FFR was calculated as the mean value of Pd/Pa. For FFR values between 0.75 and 0.80, the decision regarding revascularization was at the operator's discretion. All the revascularization procedures for PCI or bypass surgery were performed using standard techniques. 7, 8 Second-generation drug-eluting stents were routinely used. Routine follow-up angiography after the index procedure was highly discouraged.
Quantitative coronary angiography and intravascular ultrasound
Quantitative coronary angiography was performed using standard techniques and automated edge-detection algorithms (CAAS-5, Pie Medical, Maastricht, Netherlands). Diameter stenosis, minimal lumen diameter, elevation of the CK-MB fraction to more than 10 times the upper normal limit. Target vessel revascularization was defined as any PCI or bypass surgery of the index vessel with FFR measurement. All outcomes of interest were confirmed by source documentation collected at each hospital, and were centrally adjudicated by an independent clinical events committee.
Data and follow-up
The data were collected using a web-based dedicated case report form. Members of the academic co-ordinating centre (Clinical Research Center, Asan Medical Center, Seoul, South Korea) monitored and verified the data in the participating hospitals. Clinical follow-ups were conducted during hospitalization, at 30 days, 6 months, and 12 months after the index procedure and subsequently at 6 month intervals. The patients' clinical status, interventions, and adverse events were recorded at each visit.
Statistical analysis
Baseline characteristics are presented as a number (%) for categorical variables and mean ± standard deviation for continuous variables. Differences between groups were analysed using the Student's t-test or the Mann-Whitney U-test for continuous variables and the v 2 test or the Fisher's exact test for categorical variables, as appropriate. Survival curves were constructed using Kaplan-Meier estimates and compared with the log-rank test. Multivariable Cox proportional hazard regression models were used to adjust for the differences in the baseline characteristics between the groups. 20 Additional adjustments were made with propensity score matching and weighted Cox proportional hazards regression models with inverse probability of treatment weighting (IPTW). The propensity score was computed by a logistic regression model, and the matching was performed using the nearest neighbour method, with a calliper width of 0.2 standard deviation. [21] [22] [23] In the matched cohorts, survival curves were constructed using Kaplan-Meier estimates and compared using a Cox proportional hazard regression model. The statistical analyses were performed using SPSS version 21.0 (IBM Corporation, Armonk, NY, USA) and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria). P-values <0.05 were considered statistically significant.
Results
Between August 2009 and October 2016, 10 881 lesions from 7735 patients were prospectively enrolled in the IRIS-FFR registry, of which 1388 de novo native coronary lesions in 1334 patients were with an FFR value in the grey zone (0.75-0.80). Among these, 1334 lesions were selected (one per patient) for the patient-level analysis ( Figure 1) . After FFR assessment, revascularization was deferred for 683 lesions (deferred group) and performed in 651 lesions (performed group). The mean age of the patients was 64 years; 76% were men, 78% had stable angina, 32% were diabetic, and 59% had multi-vessel coronary artery disease. The deferred group patients were more likely to be men, and have a history of previous PCI and were associated with higher FFR values, less multi-vessel disease, less frequent left main or proximal diseases, and less complex coronary artery disease ( Table 1 and Supplementary material online, Table S1 ).
Quantitative coronary angiography showed larger minimal lumen diameters and smaller diameter stenosis in the deferred group, whereas IVUS showed that the deferred group patients had fewer plaque ruptures, larger MLA, and smaller plaque burden than the performed group patients ( Table 2) . Reference lumen diameter (mm) 3.1 ± 0. Table 3) . Indications for target lesion revascularization are summarized in Supplementary material online, Table S2 . Figure 2 shows the Kaplan-Meier curves for the outcomes in the two groups. Independent predictors of MACE in the deferred and performed groups are shown in Supplementary material online, Tables S3 and S4.
Outcomes for the overall population
Outcomes for the propensity scorematched groups
Propensity score matching to adjust for the differences in the baseline characteristics created 368 matched pairs of patients. The two groups were well balanced with no significant differences in baseline characteristics, except for the more frequent post-procedural use of antiplatelet agents and statin in the performed group ( Table 1) . The clinical outcomes showed a similar trend to those for the overall population. The risk of MACE, death, cardiac death, and spontaneous MI did not differ between the groups (Table 3, Figure 3 ). The results after adjustment by IPTW were consistent ( Table 3) . The clinical outcomes of the patients not included in the propensity score matching showed a similar trend (see Supplementary material online, Tables S5 and S6).
Subgroup analyses
In the subgroup analyses, the only difference in the effect on MACE between deferred and performed revascularization was with respect to MLA on IVUS (< _2.5 mm 2 and >2.5 mm 2 ), in which a trend towards a treatment by subgroup interaction was observed (P = 0.045 for the interaction; Figure 4 ). Even when a stricter definition of periprocedural MI was applied, the overall findings remained consistent (see Supplementary material online, Table S7 ).
Discussion
Data from this large, prospective, multicentre registry showed that the risk of a composite of death, target vessel MI and TVR for patients with grey-zone FFR values did not significantly differ between the patients whose revascularization was deferred and those for whom it was performed. The incidence of death and spontaneous MI did not differ between the groups. Although the risk of TVR tended to be higher for the deferred group, this was offset by a higher risk of periprocedural MI for the performed group. This trend remained consistent even after adjustment by propensity score matching and IPTW. This suggests that the medical treatment of lesions with grey-zone FFR values would be a reasonable and safe strategy. Revascularization may be considered in patients with medically refractory angina.
Initially, the FFR cut-off value for revascularization was 0.75, with FFR values <0.75 having >99% positive predictive value for inducible myocardial ischaemia. Subsequent studies have reported that in a minority of patients, FFR between 0.75 and 0.80 was associated with flow-limiting stenosis. 24, 25 Currently, FFR of 0.80 is used in revascularization threshold to avoid a few significant stenosis being left untreated. reported that revascularization was associated with lower rates of MACE and spontaneous MI. The IRIS-FFR registry includes the largest current cohort of prospectively enrolled coronary stenosis patients treated using contemporary medicine and interventional technology, with clinical events adjudicated by an independent committee. Furthermore, we controlled for selection bias between the groups in the present study using various statistical adjustments. This study could therefore provide valuable insights for daily catheterization laboratory practice.
The results suggested that deferred revascularization could be the preferred initial treatment strategy for stenosis with grey-zone FFR values. In the deferred group, the annual death and target vessel MI rate was less than 1%. The annual incidence of TVR was less than 2%, which must be lower than that of contemporary PCI-related complications. 27, 28 Late TVR after index procedure was more frequent in the deferred group. However, it is noteworthy that in performed group, all patients already received PCI and 3.7% experienced late TVR. Therefore, more patients actually received stent implantation in performed group than deferred group between index procedure and follow-up. Although we exclusively used second-generation drugeluting stents, the risk of periprocedural MI and repeated TVR was not negligible in the performed group, and performing revascularization was not observed to be superior to medical treatment for stenosis with grey-zone FFR values. These overall findings remained consistent even when we applied a stricter definition of periprocedural MI in a supplementary analysis. A recent meta-analysis showed that the outcome-derived FFR threshold for revascularization was located within the grey zone 29 that was consistent with our findings.
The morphological characteristics of the stenosis and the patient's clinical context can affect clinical outcomes in coronary artery disease. 15, 30, 31 Thus, for stenosis with grey-zone FFR values, some operators favour revascularization for high-risk patients and lesion characteristics, such as patients with diabetes or acute coronary syndrome. However, our subgroup analysis showed no differences in effect between deferred and performed revascularization on the risk of MACE across the subgroups including acute coronary syndrome. This would be due to that unfavourable clinical and lesion characteristics affected outcomes of both revascularized and deferred lesions. Interestingly, MLA showed a marginally significant interaction. However, these results had insufficient statistical power and should be interpreted with caution.
A further large study is needed to test whether MLA measured using IVUS could guide revascularization decisions for stenosis with grey-zone FFR values. 
Limitation
This study has several limitations. First, there was the inherent limitation of this being an observational study. Second, the clinical and lesion characteristics differed between the groups. These differences were adjusted through propensity score matching; nevertheless, some differences remained, particularly with regard to the use of post-procedural medications. Third, we selected one lesion per patient to eliminate clustering effects. Additional analysis with the all 1388 lesions showed similar trends (Supplementary Tables S9 and S10). Finally, the power of this study could be limited to detect small differences. Our findings warrant substantiation in larger studies with greater power. Although underpowered, this study is the largest cohort of prospectively enrolled patients with the longest follow-up duration that could give clinically relevant information for the debating issue.
Conclusion
In conclusion, this study based on a large, prospective, and multicentre registry demonstrated that revascularization was not associated with better clinical outcomes for coronary stenosis with greyzone FFR values. A high risk of periprocedural MI in patients who underwent revascularization was offset by the high risk of TVR in the deferred group.
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